Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 8/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13622143 | 0.87 | RYR2 (0.60) | RYR2NOTUMKCNH2MEN1KMT2A | |
| SCHEMBL11627236 | 0.85 | RYR2 (0.44) | RYR2NOTUMHSD17B3MEN1KMT2A | |
| SCHEMBL15705417 | 0.82 | RYR2 (0.43) | RYR2NOTUM | |
| SCHEMBL9636604 | 0.80 | RYR2 (0.54) | RYR2NOTUMKCNH2ALDH1A1 | |
| SCHEMBL6867950 | 0.79 | RYR2 (0.65) | RYR2 | |
| SCHEMBL12226485 | 0.77 | NOTUM (0.55) | NOTUMHSD17B3MEN1KMT2AALDH1A1 | |
| SCHEMBL7560987 | 0.77 | RYR2 (0.72) | RYR2NOTUMKCNH2HSD17B3 | |
| SCHEMBL15936312 | 0.77 | RYR2 (0.51) | RYR2NOTUMKCNH2KDM4EDRD4 | |
| SCHEMBL12226492 | 0.76 | MEN1 (0.61) | NOTUMMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL14862467 | 0.76 | RYR2 (0.50) | RYR2NOTUMKCNH2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090292119-A1 | METHODS FOR SYNTHESIZING BENZOTHIAZEPINE COMPOUNDS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292119-A1 | METHODS FOR SYNTHESIZING BENZOTHIAZEPINE COMPOUNDS | KCNB2, KCNJ2, KCNJ5 | RYR2 275/4885NOTUM 336/4885KCNH2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.